- Products & Services
- Knowledge Base
An available non-invasive device to measure PRV/HRV offers a potential biomarker of COVID-19 infection where a reliable, rapid, and laboratory-free screening method is needed." - Patrick Nemechek D.O.
OVERLAND PARK, KS, September 04, 2020 /24-7PressRelease/ -- Nemechek Technologies announced the publication of a peer-reviewed article by its CEO, Patrick Nemechek D.O. Entitled, 'Pulse Rate Variability as a Biomarker of COVID-19 Infection, Hospital Risk Stratification, and Post Hospitalization Recovery', the article explains the use of a simple, non-invasive method for early diagnosis of infection in asymptomatic and pre-symptomatic individuals.
Heart rate variability (HRV), the variation in time between heartbeats, is a recognized measure of autonomic nervous system (ANS) health. The degree of variability can indicate the presence of illness and inflammatory pathologies. High HRV indicates a healthy person with a well-functioning ANS and low inflammation. Low HRV indicates ANS dysfunction and is associated with elevated inflammation and poor outcomes in a variety of medical conditions.
HRV can be measured indirectly by measuring pulse rate variability (PRV). The Nemechek Technologies PRV device, "MyVagus Sensor", is worn on the finger and communicates via Bluetooth with an app called "MyAutonomic Health". PRV is determined by analyzing capillary pulse waves for one minute and reflect the impact of inflammation on nervous system health. PRV scores can be graphically displayed showing if the systemic inflammatory status is increasing or decreasing.
Read the article
Founded by Patrick Nemechek, D.O., and Jean Nemechek in 2019, Nemechek Technologies, LLC is a privately-held manufacturer of bio-electronic medicine. Their first product, the Vitality Smartcable®, is the first taVNS neuromodulator that runs on a smartphone. Nemechek Technologies is currently sponsoring a clinical trial using Vitality Smartcable® devices as a COVID-19 therapy.
With 20 years' experience as an HIV physician and researcher, Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of lowering inflammation and reversing autonomic nervous system damage. The Nemechek Protocol®, which focuses on the reduction of chronic inflammation, includes the use of transcutaneous vagus nerve stimulation. Dr. Nemechek has treated more than 1,000 patients with vagus nerve stimulation therapy over the past ten years at his clinic near Phoenix, Ariz.
# # #